Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_31fb964e2148aff14f5bfc5f5ae6fbaf |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-685 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1275 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-685 |
filingDate |
2015-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2016-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2c95b288f4744ef293ec56f97421182 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_664d578b517880c96e83ba54ae7cf671 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96e074154e253a06f19349d2369e586d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae05fbcdd31aff2f1ac37870fb4b4cd8 |
publicationDate |
2016-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-9439946-B2 |
titleOfInvention |
Reconstituted high density lipoprotein formulation and production method thereof |
abstract |
A reconstituted high density lipoprotein formulation having relatively low toxicity comprises an apolipoprotein such as ApoAI or fragment thereof, a lipid and a detergent at a level which is about 5-50% of that which would normally cause liver toxicity upon administration to a human. The lipid is optimally phosphatidylcholine at about 30-50 g/L and the molar ratio of apolipoprotein:lipid is optimally in the range 1:40 to 1:75. The formulation is useful for treating diseases or conditions such as cardiovascular disease, hypercholesterolaemia and hypocholesterolaemia inclusive of acute coronary syndrome (ACS), atherosclerosis and myocardial infarction. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10335457-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11723953-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10603355-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022133852-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11464828-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018019911-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9925236-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11058747-B2 |
priorityDate |
2010-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |